Ex-Merck unit Poxel seeks IPO to finalise diabetes drug
Poxel, a French pharmaceuticals company that was spun out of Merck Serono in 2009, has filed a document de base for an IPO.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: